JPMorgan Chase & Co. Trims Stock Holdings in MiMedx Group, Inc $MDXG

JPMorgan Chase & Co. reduced its holdings in shares of MiMedx Group, Inc (NASDAQ:MDXG) by 21.3% in the third quarter, according to its most recent filing with the SEC. The fund owned 493,661 shares of the company’s stock after selling 133,744 shares during the period. JPMorgan Chase & Co. owned about 0.33% of MiMedx Group worth $3,446,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. Legato Capital Management LLC increased its stake in MiMedx Group by 18.5% in the third quarter. Legato Capital Management LLC now owns 17,341 shares of the company’s stock worth $121,000 after purchasing an additional 2,708 shares during the period. HighMark Wealth Management LLC grew its holdings in shares of MiMedx Group by 5.4% in the third quarter. HighMark Wealth Management LLC now owns 55,878 shares of the company’s stock worth $390,000 after purchasing an additional 2,878 shares during the last quarter. SkyView Investment Advisors LLC increased its stake in MiMedx Group by 3.6% in the 2nd quarter. SkyView Investment Advisors LLC now owns 87,734 shares of the company’s stock worth $523,000 after buying an additional 3,032 shares during the period. Rafferty Asset Management LLC lifted its holdings in MiMedx Group by 5.2% during the 3rd quarter. Rafferty Asset Management LLC now owns 66,240 shares of the company’s stock valued at $462,000 after buying an additional 3,262 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in MiMedx Group by 5.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 73,518 shares of the company’s stock worth $559,000 after acquiring an additional 4,049 shares in the last quarter. Hedge funds and other institutional investors own 79.15% of the company’s stock.

MiMedx Group Price Performance

NASDAQ MDXG opened at $3.92 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.92 and a current ratio of 4.32. The firm’s 50 day moving average price is $4.72 and its 200-day moving average price is $6.08. MiMedx Group, Inc has a 52-week low of $3.77 and a 52-week high of $7.99. The company has a market cap of $582.39 million, a PE ratio of 12.25 and a beta of 1.65.

MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings data on Wednesday, February 25th. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.05. The company had revenue of $118.10 million during the quarter, compared to the consensus estimate of $106.78 million. MiMedx Group had a net margin of 11.60% and a return on equity of 29.37%. Sell-side analysts forecast that MiMedx Group, Inc will post 0.3 EPS for the current fiscal year.

Analyst Ratings Changes

MDXG has been the subject of several research analyst reports. Lake Street Capital decreased their price target on shares of MiMedx Group from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, January 20th. Cantor Fitzgerald reduced their price objective on MiMedx Group from $12.00 to $8.00 and set an “overweight” rating on the stock in a report on Tuesday, February 17th. Wall Street Zen lowered MiMedx Group from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Weiss Ratings reiterated a “hold (c)” rating on shares of MiMedx Group in a report on Monday, December 29th. Finally, UBS Group set a $10.00 price target on MiMedx Group in a research report on Monday, February 23rd. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $9.60.

MiMedx Group Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.